Tag - NRXP

Developments

NRx Pharmaceuticals submits IND for chronic pain

NRx Pharmaceuticals (NASDAQ:NRXP) submitted an investigational new drug (IND) application to the FDA for the use of NRX-101 to treat chronic pain. The IND application leverages pioneering research on the use of D...

August 30, 2023

Markets

Dawson James ups NRx Pharma PT to $9 from $3

Dawson James Securities raised its price target for NRx Pharmaceuticals (NASDAQ:NRXP) to $9 from $3, saying the company’s NRX-101 drug candidate could change the treatment paradigm for depression, PTSD, and related...

April 3, 2023

Markets

Dawson James starts NRx Pharma at buy; PT $3.00

Dawson James Securities initiated coverage of NRx Pharmaceuticals (NASDAQ:NRXP) with a “buy” rating and $3.00 price target. The stock closed at 68 cents on March 16. NRx Pharmaceuticals is a clinical-stage...

March 17, 2023

Tag - NRXP

NRx Pharmaceuticals submits IND for chronic pain

Dawson James ups NRx Pharma PT to $9 from $3

Dawson James starts NRx Pharma at buy; PT $3.00

General

More